Actor profile

Altesa BioSciences

Track Altesa BioSciences's public claims and predictions. 1 claim tracked with 0% accuracy on FactTracker.

Type: organization
Tracked claims: 1
Resolved claims: 0
Accuracy: 0%

Recent claims

an abstract featuring new clinical data on vapendavir -- the company's investigational oral rhinovirus capsid inhibitor -- has been accepted for an oral presentation at the European Respiratory Society (ERS) International Congress 2026 taking place September 5–9, 2026, in Barcelona, Spain.
Jul 7, 2026